Jeffreyh Buchalter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeffreyh buchalter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeffreyh Buchalter Today - Breaking & Trending Today

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, Off-the-Shelf Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma

(0)
Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021
BEDMINSTER, N.J. and SINGAPORE, May 14, 2021) testing TT11X in patients with CD30+ lymphomas. The results will be presented today at the 24
th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021).
The presentation at ASGCT 2021 will highlight data from six patients treated with the therapy. The results demonstrated a favorable safety profile with encouraging clinical activity even at lower dose levels in heavily pre-treated relapsed / refractory (R/R) CD30+ lymphoma patients. The dataset includes three patients dosed at the lowest dosing level (4 × 10 ....

United States , Malcolm Brenner , Ingrid Mezo , Johanna Bennett , Carlos Ramos , Dave Schemelia , Allogeneic Vsts , Kostenloser Wertpapierhandel , Jeffreyh Buchalter , Tiberend Strategic Advisors Inc , Tessa Scientific Co , Meeting Of American Society Gene , Us Food Drug Administration , Baylor College Of Medicine , Presented Today , Encouraging Clinical Activity , Final Data Readout Expected , Annual Meeting , American Society , Cell Therapy , Lead Principal Investigator , Gene Therapy , Danl Duncan Comprehensive Cancer Center , Baylor College , Virus Specifict Cells , Scientific Co Founder ,

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

(0)
82 Patient Pivotal cohort expected to commence in second half of 2021
BEDMINSTER, N.J. and SINGAPORE, April 30, 2021) in relapsed / refractory Classical Hodgkin Lymphoma (R/R cHL). The next step in the two-part study is enrollment of the 82 patient Pivotal cohort to assess the safety and antitumor efficacy of Tessa s autologous CD30 CAR-T in R/R cHL, which is planned to commence in 2H 2021.
Tessa s CD30 CAR-Ts previously demonstrated excellent safety and efficacy in heavily pre-treated R/R cHL patients across two independent Phase 1/2 studies. It is exciting to see the rapid enrollment of the Pilot cohort, and we look forward to working with Tessa in the pivotal cohort of this trial. There is a high unmet need for effective treatments in R/R cHL and we are pleased to be able to advance this novel CD30 directed CAR-T cell therapy for our patients, ....

United States , Ingrid Mezo , Kostenloser Wertpapierhandel , Jeffreyh Buchalter , Johanna Bennett , Sairah Ahmed , Dave Schemelia , Tiberend Strategic Advisors Inc , Us Food Drug Administration , University Of Texas Md Anderson , European Medicines Agency , Cancer Center , Drug Administration , Classical Hodgkin Lymphoma , Associate Professor , Regenerative Medicine Advanced Therapy , European Medicines , Refractory Hodgkin , Clin Oncol , Forward Looking , Private Securities Litigation Reform Act , Strategic Advisors , ஒன்றுபட்டது மாநிலங்களில் , ஜோஹன்னா பென்னட் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் , புற்றுநோய் மையம் ,

Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study
News provided by
Share this article
BEDMINSTER, N.J. and SINGAPORE, April 30, 2021 /PRNewswire/
Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial (NCT04268706) in relapsed / refractory Classical Hodgkin Lymphoma (R/R cHL). The next step in the two-part study is enrollment of the 82 patient Pivotal cohort to assess the safety and antitumor efficacy of Tessa s autologous CD30 CAR-T in R/R cHL, which is planned to commence in 2H 2021. ....

New Jersey , United States , Jeffreyh Buchalter , Sairah Ahmed , Tessa Therapeutics Ltd , Us Food Drug Administration , Drug Administration , University Of Texas Md Anderson , European Medicines Agency , Cancer Center , European Medicine Agency , Tessa Therapeutics , Classical Hodgkin Lymphoma , Associate Professor , Hodgkin Lymphoma , Chimeric Antigen Receptor , Complete Response , Regenerative Medicine Advanced Therapy , European Medicines , Refractory Hodgkin , Clin Oncol , European Medicine , Epstein Barr Virus Specifict Cells , Forward Looking , Private Securities Litigation Reform Act , புதியது ஜெர்சி ,

Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

Share this article
BEDMINSTER, N.J. and SINGAPORE, Jan. 18, 2021 /PRNewswire/
Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company s lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).
PRIME is a program launched by EMA to optimize development plans and speed up evaluation of medicines that demonstrate major therapeutic advantage over existing treatments, or otherwise benefit patients without treatment options. Through this program, EMA offers enhanced support to medicine developers including early interaction and dialogue, and a pathway for accelerated evaluation by the agency. ....

United States , Jeffreyh Buchalter , Luigi Zinzani , Ivand Horak , European Medicines Agency , University Of Bologna , Baylor College Of Medicine , Institute Of Hematology Ser , Hodgkin Lymphoma , Baylor College , North Carolina Lineberger Comprehensive Cancer , Clinical Oncology , Pier Luigi Zinzani , Chief Medical Officer , Chief Scientific Officer , Tessa Therapeuticssaid , Non Hodgkin Lymphoma , Tessa Therapeutics , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் ஆஃப் போலோக்னா , பேலர் கல்லூரி ஆஃப் மருந்து , நிறுவனம் ஆஃப் ஹீமாட்டாலஜி சேர் , ஹாட்ஜ்கின் லிம்போமா , பேலர் கல்லூரி , வடக்கு கரோலினா லிநேபேர்கேற் விரிவான புற்றுநோய் , மருத்துவ புற்றுநோயியல் ,

Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer

Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer
BEDMINSTER, N.J. and SINGAPORE, Dec. 17, 2020 /PRNewswire/
Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, today announced the appointment of David McIntyre as its Chief Financial Officer.
Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over 10 years as Chief Financial Officer of various publicly listed and privately held entities. He joins Tessa from AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), where he served as the Chief Financial Officer.
Before joining AVITA Medical, Mr. McIntyre served as a Partner with Apple Tree Partners (ATP), a multibillion-dollar life science venture capital and growth equity fund. At ATP Mr. McIntyre was responsible for ATP s medical device portfolio, together with various operating and Board functions, including acting as CFO and Head of Technical O ....

United States , New Jersey , South Australia , Kostenloser Wertpapierhandel , Jeffreyh Buchalter , David Mcintyre , University Of Technology , University Of Sydney Australia , Head Of Technical Operations At Braeburn Inc , Baker Mckenzie , Legal Practitioner Of The Supreme Court , Heartware International Inc , Master Of Business Administration Fuqua Scholar , Duke University , Chief Financial , Chief Financial Officer , Apple Tree Partners , Technical Operations , Heartware International , Business Administration , Fuqua Scholar , Certified Practicing Accountant , Legal Practitioner , Supreme Court , New South Wales , Hodgkin Lymphoma ,